{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:30:40Z","timestamp":1782779440296,"version":"3.54.5"},"reference-count":36,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016300","name":"Octapharma","doi-asserted-by":"publisher","award":["Not applicable."],"award-info":[{"award-number":["Not applicable."]}],"id":[{"id":"10.13039\/501100016300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["463407"],"award-info":[{"award-number":["463407"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,8,2]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Reduced thrombin generation is an important component of post cardiopulmonary bypass (CPB) coagulopathy. To replenish coagulation factors and enhance thrombin generation in bleeding surgical patients, frozen plasma (FP) and four-factor prothrombin complex concentrate (4F-PCC) are used. However, the efficacy\u2013safety balance of 4F-PCC relative to FP in cardiac surgery is unconfirmed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>LEX-211 (FARES-II) is an active-control, randomised, phase 3 study comparing two coagulation factor replacement therapies in bleeding adult cardiac surgical patients at 12 hospitals in Canada and the USA. The primary objective is to determine whether 4F-PCC (Octaplex\/Balfaxar, Octapharma) is clinically non-inferior to FP for haemostatic effectiveness. Inclusion criteria are any index (elective or non-elective) cardiac surgery employing CPB and coagulation factor replacement with 4F-PCC or FP ordered in the operating room for bleeding management. Patients will be randomised to receive 1500 or 2000 international units of 4F-PCC or 3 or 4 units of FP, depending on body weight. The primary endpoint of haemostatic treatment response is \u2018effective\u2019 if no additional haemostatic intervention is required from 60\u2009min to 24 hours after the first initiation of 4F-PCC or FP; or \u2018ineffective\u2019 if any other haemostatic intervention (including a second dose of study drug) is required. An estimated 410 evaluable patients will be required to demonstrate non-inferiority (one-sided \u03b1 of 0.025, power \u226590%, non-inferiority margin 0.10). Secondary outcomes include transfusions, bleeding-related clinical endpoints, coagulation parameters and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>The trial has been approved by the institutional review boards of all participating centres. Trial completion is anticipated at the end of 2024, and results will be disseminated via publications in peer-reviewed journals and conference presentations in 2025. The results will advance our understanding of coagulation management in bleeding surgical patients, potentially reducing the need for allogeneic blood products and improving outcomes in surgical patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05523297\">NCT05523297<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-091381","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:51:27Z","timestamp":1724287887000},"page":"e091381","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Protocol for a phase 3, randomised, active-control study of four-factor prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgery patients requiring coagulation factor replacement: the LEX-211 (FARES-II) trial"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05523297","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-5660","authenticated-orcid":false,"given":"Keyvan","family":"Karkouti","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Anesthesia and Pain Management, University Health Network, Sinai Health, Women's College Hospital, Toronto, Ontario, Canada"},{"name":"Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Callum","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Bartoszko","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Anesthesia and Pain Management, University Health Network, Sinai Health, Women's College Hospital, Toronto, Ontario, Canada"},{"name":"Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Solomon","sequence":"additional","affiliation":[{"name":"Octapharma AG, Lachen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Knaub","sequence":"additional","affiliation":[{"name":"Octapharma AG, Lachen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-4962","authenticated-orcid":false,"given":"Jerrold H","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Duke University, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5051-1365","authenticated-orcid":false,"given":"Kenichi A","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The University of Oklahama Health Sciences Centre, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"2025101815165565000_14.8.e091381.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020741","article-title":"Protocol for a phase III, non-inferiority, randomised comparison of a new fibrinogen concentrate versus cryoprecipitate for treating acquired hypofibrinogenaemia in bleeding cardiac surgical patients: the FIBRES trial","volume":"8","author":"Karkouti","year":"2018","journal-title":"BMJ Open"},{"key":"2025101815165565000_14.8.e091381.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.04144.x"},{"key":"2025101815165565000_14.8.e091381.3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/jth.15195","article-title":"Managing the coagulopathy associated with cardiopulmonary bypass","volume":"19","author":"Bartoszko","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025101815165565000_14.8.e091381.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.148"},{"key":"2025101815165565000_14.8.e091381.5","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s12630-020-01609-4","article-title":"Thrombin generation and bleeding in cardiac surgery: a clinical narrative review","volume":"67","author":"Fitzgerald","year":"2020","journal-title":"Can J Anaesth"},{"key":"2025101815165565000_14.8.e091381.6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1160\/TH16-02-0094","article-title":"A reduction of prothrombin conversion by cardiac surgery with cardiopulmonary bypass shifts the haemostatic balance towards bleeding","volume":"116","author":"Kremers","year":"2016","journal-title":"Thromb Haemost"},{"key":"2025101815165565000_14.8.e091381.7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00298.x"},{"key":"2025101815165565000_14.8.e091381.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2010.11.078"},{"key":"2025101815165565000_14.8.e091381.9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3936","article-title":"Comparison of 4-Factor Prothrombin Complex Concentrate With Frozen Plasma for Management of Hemorrhage During and After Cardiac Surgery: A Randomized Pilot Trial","volume":"4","author":"Karkouti","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025101815165565000_14.8.e091381.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02798.x"},{"key":"2025101815165565000_14.8.e091381.11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/trf.12970","article-title":"A multicenter study of plasma use in the United States","volume":"55","author":"Triulzi","year":"2015","journal-title":"Transfusion"},{"key":"2025101815165565000_14.8.e091381.12","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeu086"},{"key":"2025101815165565000_14.8.e091381.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03663.x"},{"key":"2025101815165565000_14.8.e091381.14","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000001188"},{"key":"2025101815165565000_14.8.e091381.15","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/ALN.0000000000002399","article-title":"Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal","volume":"129","author":"Levy","year":"2018","journal-title":"Anesthesiology"},{"key":"2025101815165565000_14.8.e091381.16","doi-asserted-by":"crossref","DOI":"10.21470\/1678-9741-2023-0076","article-title":"Hemostasis Using Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: Systematic Review with Meta-Analysis","volume":"39","author":"Li","year":"2024","journal-title":"Braz J Cardiovasc Surg"},{"key":"2025101815165565000_14.8.e091381.17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.athoracsur.2018.10.013","article-title":"Prothrombin Complex Concentrate in Cardiac Surgery: A Systematic Review and Meta-Analysis","volume":"107","author":"Roman","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2025101815165565000_14.8.e091381.18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5090\/jcs.23.081","article-title":"Prothrombin Complex Concentrate versus Fresh Frozen Plasma in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis","volume":"57","author":"Viana","year":"2024","journal-title":"J Chest Surg"},{"key":"2025101815165565000_14.8.e091381.19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/anae.15327","article-title":"Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial)","volume":"76","author":"Green","year":"2021","journal-title":"Anaesthesia"},{"key":"2025101815165565000_14.8.e091381.20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamasurg.2022.2235","article-title":"Prothrombin Complex Concentrate vs Plasma for Post-Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial","volume":"157","author":"Smith","year":"2022","journal-title":"JAMA Surg"},{"key":"2025101815165565000_14.8.e091381.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.023956"},{"key":"2025101815165565000_14.8.e091381.22","unstructured":"Government of Canada.Panel on Research Ethics . Tri-council policy statement: ethical conduct for research involving humans \u2013 TCPS 2 2022, 2022. Available: https:\/\/ethics.gc.ca\/eng\/policy-politique_tcps2-eptc2_2022.html [Accessed 1 Jul 2024]."},{"key":"2025101815165565000_14.8.e091381.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2016.09.022"},{"key":"2025101815165565000_14.8.e091381.24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/1076029617753537","article-title":"Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P\/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation","volume":"24","author":"Chowdary","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025101815165565000_14.8.e091381.25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.bja.2018.02.017","article-title":"Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma","volume":"120","author":"Fitzgerald","year":"2018","journal-title":"Br J Anaesth"},{"key":"2025101815165565000_14.8.e091381.26","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318264c644"},{"key":"2025101815165565000_14.8.e091381.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782060"},{"key":"2025101815165565000_14.8.e091381.28","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1636541"},{"key":"2025101815165565000_14.8.e091381.29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40560-018-0303-y","article-title":"Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors","volume":"6","author":"Tao","year":"2018","journal-title":"J Intensive Care"},{"key":"2025101815165565000_14.8.e091381.30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/cc11322","article-title":"ROTEM\u00ae-guided coagulation factor concentrate therapy in trauma: 2-year experience in Venice, Italy","volume":"16","author":"Grassetto","year":"2012","journal-title":"Crit Care"},{"key":"2025101815165565000_14.8.e091381.31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002283"},{"key":"2025101815165565000_14.8.e091381.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2013.10.070"},{"key":"2025101815165565000_14.8.e091381.33","doi-asserted-by":"crossref","unstructured":"Wassmer G , Brannath W . Group sequential and confirmatory adaptive designs in clinical trials. In: Springer Series in Pharmaceutical Statistics. 1st edn. Springer, 2016.","DOI":"10.1007\/978-3-319-32562-0"},{"key":"2025101815165565000_14.8.e091381.34","unstructured":"U.S. Food and Drug Administration . CFR - code of federal regulations title 21, chapter I, subchapter D, part 312. 2024. Available: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-312?toc=1 [Accessed 1 Jul 2024]."},{"key":"2025101815165565000_14.8.e091381.35","unstructured":"U.S. Food and Drug Administration . CFR - code of federal regulations title 21, chapter I, subchapter A, part 50-protection of human subjects. 2024. Available: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-A\/part-50?toc=1 [Accessed 1 Jul 2024]."},{"key":"2025101815165565000_14.8.e091381.36","unstructured":"U.S. Food and Drug Administration . CFR - code of federal regulations title 21, chapter I, subchapter A, part 56-institutional review boards. 2024. Available: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-A\/part-56?toc=1 [Accessed 1 Jul 2024]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-091381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:17:04Z","timestamp":1760825824000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-091381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,21]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/bmjopen-2024-091381"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-091381","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}